Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Inclusion Criteria:

18 years of age or older
Histologically documented diagnosis of mucosal melanoma or acral melanoma or chronically sun damaged melanoma as evidenced by solar elastosis on pathology
Patient's tumor with evidence for KIT mutation or amplification. Patient tumors that already have documented mutations or amplification do not have to have tissue submitted again for analysis to confirm eligibility
Have failed, progressed, or not been able to tolerate other tyrosine kinase inhibitors including but not limited to imatinib mesylate, sunitinib or dasatinib treatment.
At least one measurable site of disease
ECOG Performance Status 0, 1 or 2
Adequate organ function as outlined in the protocol
Negative pregnancy test for female patients of childbearing potential

Exclusion Criteria:

Patient has received any other investigational agents within 28 days of first day of study drug dosing unless the disease is rapidly progressing
Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
Female patients who are pregnant or breast-feeding
Patient has a severe and/or uncontrolled medical disease
Patient has a rare hereditary problem of galactose intolerance, severe lactase deficiency or of glucose-galactose malabsorption
Patient with electrolyte abnormality unless the level can be corrected to normal levels prior to initiating study drug
Known brain metastasis
Known chronic liver disease
Patient has received chemotherapy within 4 weeks prior to study entry, unless the disease is rapidly progressing (6 weeks for nitrosourea or mitomycin-C)
Patient previously received radiotherapy to 25% or greater of the bone marrow
Patient had a major surgery within 2 weeks prior to study entry
Impaired cardiac function
QTc > 450msec on screening ECG
Myocardial infarction within one year prior to starting nilotinib
Other clinically significant heart disease
Patients who are currently receiving treatment with any of the medications that have the potential to prolong QT interval
Patients who are currently receiving Warfarin > 1mg/day
Patient with any significant history of non-compliance to medical regimens or with the inability to grant reliable informed consent
Prior therapy with nilotinib